An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma-Reference-Cited by-同舟云学术

An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma

Author:

Nishihori Taiga¹²,Baz Rachid²³,Shain Kenneth²³,Kim Jongphil²⁴,Ochoa-Bayona Jose L.¹²,Yue Binglin⁴,Sullivan Daniel¹²,Dalton William²³,Alsina Melissa¹²

Affiliation:

1. Department of Blood and Marrow Transplantation; H. Lee Moffitt Cancer Center and Research Institute; Tampa FL USA

2. Chemical Biology and Molecular Medicine Program; H. Lee Moffitt Cancer Center and Research Institute; Tampa FL USA

3. Department of Malignant Hematology; H. Lee Moffitt Cancer Center and Research Institute; Tampa FL USA

4. Biostatistics core; H. Lee Moffitt Cancer Center and Research Institute; Tampa FL USA

Publisher

Wiley

Subject

Hematology,General Medicine

Link

Reference38 articles.

1. Multiple myeloma;Kyle;Blood,2008

2. Multiple myeloma;Palumbo;N Engl J Med,2011

3. Treatment of multiple myeloma;Rajkumar;Nat Rev Clin Oncol,2011

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献